(Reuters) - The United States-Mexico-Canada Agreement has no provisions that would force changes to U.S. laws with respect to pharmaceutical companies, U.S. Trade Representative Robert Lighthizer said on Tuesday.

“To the extent that a member (of Congress) thinks anything in here will stop you from changing laws, then we have to correct that,” Lighthizer said at a hearing of the Senate Finance Committee.